Literature DB >> 18558359

Role of natural antibodies in immune homeostasis: IVIg perspective.

Janakiraman Vani1, Sriramulu Elluru, Vir-Singh Negi, Sébastien Lacroix-Desmazes, Michel D Kazatchkine, Jagadeesh Bayry, Jagadeesh Bayary, Srini V Kaveri.   

Abstract

Intravenous immunoglobulin (IVIg) has increasingly been used for the treatment of autoimmune and systemic inflammatory diseases in addition to supportive therapy of immunodeficient patients. Although a considerable progress has been made in understanding the mechanisms by which IVIg exerts immunomodulatory functions in these diseases, they remain not fully elucidated. The mode of action of IVIg is complex, involving interference with activation of complement and the cytokine network, modulation of: idiotype network, expression of Fc receptors, and activation, differentiation and effector functions of T and B cells and of antigen-presenting cells such as dendritic cells. The therapeutic effects of IVIg most likely reflect the functions of natural antibodies in maintaining immune homeostasis in healthy individuals.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18558359     DOI: 10.1016/j.autrev.2008.04.011

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  24 in total

Review 1.  Immunological origin and functional properties of catalytic autoantibodies to amyloid beta peptide.

Authors:  Sudhir Paul; Stephanie Planque; Yasuhiro Nishiyama
Journal:  J Clin Immunol       Date:  2010-05       Impact factor: 8.317

2.  Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients.

Authors:  Mohan S Maddur; Magalie Rabin; Pushpa Hegde; Francis Bolgert; Moneger Guy; Jean-Michel Vallat; Laurent Magy; Jagadeesh Bayry; Srini V Kaveri
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Natural autoantibodies to Fcγ receptors in intravenous immunoglobulins.

Authors:  Hicham Bouhlal; Denis Martinvalet; Jean-Luc Teillaud; Catherine Fridman; Michel D Kazatchkine; Jagadeesh Bayry; Sébastien Lacroix-Desmazes; Srini V Kaveri
Journal:  J Clin Immunol       Date:  2014-04-01       Impact factor: 8.317

4.  Prevention of excessive collagen accumulation by human intravenous immunoglobulin treatment in a murine model of bleomycin-induced scleroderma.

Authors:  M Kajii; C Suzuki; J Kashihara; F Kobayashi; Y Kubo; H Miyamoto; T Yuuki; T Yamamoto; T Nakae
Journal:  Clin Exp Immunol       Date:  2010-11-22       Impact factor: 4.330

5.  Autoantibodies to the delta-opioid receptor function as opioid agonists and display immunomodulatory activity.

Authors:  Parvathi Ranganathan; Hao Chen; Miranda K Adelman; Samuel F Schluter
Journal:  J Neuroimmunol       Date:  2009-10-30       Impact factor: 3.478

6.  Non-ST Elevation Myocardial Infraction after High Dose Intravenous Immunoglobulin Infusion.

Authors:  Meir Mizrahi; Tomer Adar; Efrat Orenbuch-Harroch; Yair Elitzur
Journal:  Case Rep Med       Date:  2010-02-22

Review 7.  Special considerations with the use of intravenous immunoglobulin in older persons.

Authors:  M Jennifer Cheng; Colleen Christmas
Journal:  Drugs Aging       Date:  2011-09-01       Impact factor: 3.923

8.  Efficacy of intravenous immunoglobulin (IVIG) affinity-purified anti-desmoglein anti-idiotypic antibodies in the treatment of an experimental model of pemphigus vulgaris.

Authors:  D Mimouni; M Blank; A S Payne; G J Anhalt; C Avivi; I Barshack; M David; Y Shoenfeld
Journal:  Clin Exp Immunol       Date:  2010-10-21       Impact factor: 4.330

9.  Modulatory role of intravenous gammaglobulin (IgIV) on the in vitro antibody response to a pneumococcal polysaccharide antigen.

Authors:  Lily E Leiva; Hanh Monjure; Ricardo U Sorensen
Journal:  J Clin Immunol       Date:  2014-12-12       Impact factor: 8.317

10.  B cells produce pathogenic antibodies and impair recovery after spinal cord injury in mice.

Authors:  Daniel P Ankeny; Zhen Guan; Phillip G Popovich
Journal:  J Clin Invest       Date:  2009-09-21       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.